Investigator Sponsored Studies, grants and sponsorships
Vertex Pharmaceuticals funds independent research and education in cystic fibrosis, pain, IgA nephropathy, and related diseases through its Investigator Sponsored Studies, grants and sponsorships program.
Browse similar grants
Funder: Vertex Pharmaceuticals
Due Dates: Rolling (CF, Pain, IgA nephropathy, most grants & sponsorships) | RFP-based (Beta thalassemia & Sickle cell disease; currently closed)
Funding Amounts: No fixed cap; budgets must be reasonable and not exceed 35% overhead for ISS. Typical CF Research Innovation Awards: up to $750,000 over 3 years.
Summary: Supports independent research, education, and sponsorships advancing care and knowledge in cystic fibrosis, pain, IgA nephropathy, and other serious diseases.
Key Information: ISS and grants must align with Vertex’s disease area priorities; pain proposals accepted only from U.S. institutions.
Description
Vertex Pharmaceuticals offers a comprehensive external funding program supporting investigator-sponsored studies (ISS), independent grants, and sponsorships. The initiative aims to advance scientific knowledge, education, and patient advocacy in serious diseases including cystic fibrosis (CF), pain, IgA nephropathy (IgAN), beta thalassemia, sickle cell disease, and others. Funding is available for clinical, observational, and nonclinical studies, as well as for educational and advocacy programs, provided they align with Vertex’s defined areas of interest and scientific priorities.
Vertex’s ISS program supports independent research projects at academic institutions, healthcare organizations, and non-profits. Grants and sponsorships are also available for medical education, patient advocacy, and scientific advancement initiatives. Funding decisions are based on scientific merit, alignment with current Vertex priorities, and budget appropriateness.
